Ribociclib (LEE011) Rollover Study for Continued Access

This study is for people who are currently in another Novartis study and are already receiving the medicine called ribociclib. Your doctor must believe that the treatment is helping you and that you are getting a clinical benefit from it. Both men and women between the ages of 0 and 80 years old can take part, as long as they meet these specific requirements.

However, you cannot join this study if you have already permanently stopped taking ribociclib in your original study for any reason. Also, if you no longer meet the original study's rules for continuing your treatment, you would not be able to join this rollover study. The core idea is that you must be currently taking and benefiting from ribociclib in another study.

If you join this study, you will continue to receive the ribociclib treatment, just as you have been in your original study. This means you'll continue to have regular visits with your healthcare team, likely at your current clinic or hospital. During these visits, the team will check how you're feeling and how the treatment is working. They will conduct assessments, which might include blood tests, physical exams, and possibly scans, to monitor your health and the progress of your cancer. The specific schedule for these visits and tests will be similar to what you've already experienced. You will continue taking the ribociclib as prescribed, and your follow-up will continue for as long as your doctor believes the treatment is helping you and you meet the study's requirements.